These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999-2001).
    Author: Jones RN, Biedenbach DJ.
    Journal: Diagn Microbiol Infect Dis; 2003 Apr; 45(4):273-8. PubMed ID: 12729999.
    Abstract:
    Emerging resistances to orally administered antimicrobials have escalated among bacteria causing community-acquired respiratory infections (CARTI). The spectrum and potency of garenoxacin, (formerly BMS 284756) was assessed against a collection of CARTI isolates from North American medical centers during a longitudinal surveillance study, the SENTRY Antimicrobial Surveillance Program (1999-2001). A total of 8,331 strains of Hemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae were tested by reference methods and compared to numerous other marketed antimicrobials. Nearly all (95.1%) M. catarrhalis were penicillin-resistant, 27.9% of H. influenzae were ampicillin-resistant and 35.0% of S. pneumoniae had MICs at > or = 0.12 microg/ml for penicillin. Garenoxacin was very active against the three monitored species with MIC(90) values of < or =0.06 microg/ml. Garenoxacin and other quinolones were equally active against the Gram-negative pathogens (except moxifloxacin which was at least twofold less potent versus M. catarrhalis). However, against pneumococci the rank order of potency (MIC(50) in microg/ml) was: gemifloxacin (0.015) > garenoxacin (0.06) > trovafloxacin = moxifloxacin (0.12) > gatifloxacin (0.25) > levofloxacin = ciprofloxacin (1). A trend toward greater resistance worldwide was observed for ciprofloxacin (MIC, > or = 4 microg/ml), increasing from 1.5% in 1999 to 6.8% in 2001. The highest quinolone resistance rate was observed in North America. Garenoxacin, a new desfluoro(6)quinolone, was documented to be very active in vitro (MIC, < or =2 microg/ml) against > 99.9% of all CARTI isolates in the SENTRY Program. Evolving resistances to other antimicrobial classes or among currently used quinolones appear to position this investigational desfluoro(6)quinolone as a potential treatment option for future clinical use in ambulatory patients.
    [Abstract] [Full Text] [Related] [New Search]